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The aim of this study was to monitor changes in the expression of immune-related genes in the bladder after tumor implantation.
Mice were orthotopically implanted with MB49-PSA cells (C57BL/6 mice) on day 1 and terminated on days 7, 14, 21, and 28.
Another mouse model (MBT-2/C3H mice) was examined at day 7. Gene expression analysis was performed using a TaqMan Low
Density Mouse Immune Panel (Applied Biosystems, USA) on RNA extracted from the bladders. Selected genes were reconﬁrmed
by real-time PCR analysis and RT-PCR on the mRNA from other animals. Immune suppressive (IL13, IL1β, PTGS2, NOS2, IL10,
CTLA4, and CCL22) and immune stimulatory genes (CSF2, GZMB, IFNγ, CXCL10, TNFα, CD80, IL12a, and IL6) and AGTR2
were increased by day 7. By day 28, IL10, CCL2,CCL5, CXCL11,CTLA4, GZMB, IFNγ, CSF2, and IL6 were signiﬁcantly increased.
Therapeutic strategies involving TH1 induction and TH2 dampening may improve responses to immunotherapy.
1.Introduction
Bladder cancer is the 7th most common cancer worldwide.
Though bladder cancer is not usually life threatening, it is
prone to recurrences which may progress to invasive cancer.
Transurethral resection of the bladder tumor (TURBT)
followed by Mycobacterium bovis, Bacillus Calmette Guerin
(BCG) immunotherapy reduces the incidence of recurrence,
but some 30–50% of patients do not respond to therapy [1,
2]. Recurrences are attributed to remnant tumor cells missed
during surgery as a second surgical procedure prior to BCG
therapy improves the response to therapy [1]. The immune
response induced by BCG immunotherapy may inadver-
tently ensure the survival of less immunogenic remnant
tumor cells which could give rise to recurrence and progres-
sion. The increased incidence of progression in patients who
fail BCG immunotherapy gives some credence to this latter
possibility [1].
Tumor immune editing is a dynamic process that has 2
importantparticipantsthetumorcellsandtheimmunecells.
Their interaction determines whether tumor regression or
growth occurs. Orthotopic murine models of bladder cancer
generated by implanting syngenic cell lines have been used to
evaluate response to gene therapy. One such model, MB49
cells implanted in C57BL/6 mice, has been shown to be
fairly similar to human bladder cancers [3]. Several cytokine
genes have been evaluated for their ability to induce tumor
regression in this model. Intravesical delivery of IL2 cured
40% of mice [4], IFNγ cured 50–80% of mice based on
the amount of IFNγ secreting retrovirus delivered [5], TNFα
cured 67% of mice [6], IFNα singly and/or with GMCSF
cured 20–50% of mice [7, 8], adenovirus delivery of IL12
cured 88% of mice [9], and AdCD40L delivery cured 60% of
mice [10]. Tumor cells expressing IL12 and IL18 were com-
pletely rejected in mice [11]. The poor response to intraves-
ical therapy has been attributed to the inadequacies of the
gene delivery systems whether viral [12]o rn o n v i r a l[ 13,
14]. However, MB49 cells were shown by Yang and Lattime
[15] and Halak et al. [16] to induce the expression of IL10
in the bladder. IL10 is an immunosuppressive gene and
its expression may have contributed to the poor response.
Besides IL10, there may be other immunosuppressive mech-
anisms involved in the interplay between the immune system
and the tumor cells.
The aim of this study therefore was to characterize the
changes in the bladder environment after orthotopic tumor2 Clinical and Developmental Immunology
cell implantation. In general, tumors implanted in the blad-
der if not treated result in death after about 4–6 weeks. Some
mice may show spontaneous cures in this time period. To
understandtheeventsthatoccurduringtumorgrowthinthe
bladder environment, we chose to evaluate gene expression
changes soon after tumor cell implantation (7th day) and
at a later stage (28th day). Several immunosuppressive genes
were induced after tumor implantation, and these represent
possible new targets for therapy. A few mice were also
examined 14 and 21 days after tumor implantation. Our
results indicate that the TH1/TH2 balance in the tumor
environment varies with time and may inﬂuence the success
of any therapy.
2. Methods
2.1. Tumor Implantation. All animal work adhered to the
National University of Singapore, Institutional Animal Care
and use Committee (IACUC), guidelines on animal use and
handling. Four to six-week-old female C57BL/6 mice were
orthotopically implanted with MB49-PSA (prostate-speciﬁc
antigen secreting MB49 cells) [8] using poly-L-lysine (PLL)
as described by Ninalga et al. [17]. Mice were anesthetized
with 75mgketamine/kg and 1mgmedetomedine/kg of ani-
mal weight (0.1mL/10g mice body weight) prior to implan-
tation. MB49 cells were originally obtained from Prof T
Ratliﬀ, Purdue University. Brieﬂy, mice were given a bladder
instillation of 0.1mL of sterile 0.01% PLL (Sigma-Aldrich,
St. Louis, Mo, USA) for 20mins prior to instillation of the
tumor cells (1 × 106 cells/mL) for 2 hours. Control mice
were treated with PLL but not implanted with tumor cells.
PSA levels in urine were monitored using a free-PSA chemi-
luminescence ELISA kit (Autobio Diagnostics, Zhengzhou,
China) and normalized against creatinine levels using a kit
(Wako Pure Chemicals Industries, Osaka, Japan). Mice were
killed on days 7 and 28 and RNA isolated from the bladders.
For gene expression studies, 10 mice were used per group. To
determine gene expression changes with time, at least 3 mice
were sacriﬁced on days 7, 14, 21, and 28. For ﬂow cytometry
studies, 6 mice were sacriﬁced on day 28 and tissues were
pooled from 2 mice for analysis.
Similarly, four-to-six-week-old female C3H/HeJ mice
were orthotopically implanted with MBT2-PSA (prostate-
speciﬁcantigensecretingMBT2cells)whilecontrolC3H/HeJ
m i c ew e r et r e a t e dw i t hP L Lo n l y .A f t e r7d a y s ,4m i c ef r o m
each group were sacriﬁced for gene expression analysis.
2.2. RNA Isolation and Real-Time LDA Panel. Frozen blad-
ders and lymph nodes were soaked overnight in RNAlater-
ICE (Ambion, Austin, Tex, USA) at −20◦C before they were
homogenized in TRIzol Reagent (Invitrogen, Carlsbad, Calif,
USA). CDNA was reverse transcribed from total RNA (10μg
per sample) with random primers using the High-Capacity
cDNA Reverse Transcription Kit with RNase Inhibitor
(AppliedBiosystems,FosterCity,Calif,USA).MRNAexpres-
sion was analyzed using a TaqMan Low Density Mouse
Immune Panel (Applied Biosystems) containing a panel of
96 immune-related genes (cytokines, chemokines, growth
factors, immune regulators, apoptosis markers, ischemia
markers, tissue-speciﬁc markers, and others including classic
and endogenous controls) as described by Cai et al. [18].
Detection and analysis was performed on the ABI PRISM
7900HT Sequence Detection System with ABI 7900HT SDS
Software Version 2.2.1 with the following parameters: 2mins
at 50◦C, 10mins at 94.5◦C, and 40 cycles of 30s at 97◦C
for denaturation and 1min at 59.7◦C for transcription. Dif-
ferential gene expression proﬁling was performed using the
comparative CT method of relative quantitation. All samples
were loaded in triplicate, and results with CT SD ≥ 0.3 were
discarded. The lowest limit of detection is CT = 32 thus
any gene with a CT value beyond 32 is considered not
detectable. Only genes displaying at least a 2-fold diﬀerence
in expression level relative to control were considered to be
upregulated. Gene expression was conﬁrmed using real-time
PCR analysis for a select group of genes.
2.3. Real-Time PCR Analysis and RT-PCR. Real-time PCR
reactions for single genes were performed using 100ng of
reverse transcribed RNA, TaqMan universal PCR master mix
and pre formulated 20x TaqMan gene expression assay in a
96-well PCR plate. The genes and their TaqMan gene ex-
pression assay numbers are Actb Mm00607939 s1; AGTR2
Mm00431727 g1; CSF2 Mm00438328 m1; CTLA4
Mm00486849 m1; CXCR3 Mm00438259 m1; GAPDH
Mm99999915 g1; GZMB Mm00442834 m1; IFNγ
Mm00801778 m1; IL10 Mm00439616 m1; PTGS2
Mm00478374 m1; TGFb1 Mm00441724 m1; TNFα
Mm00443258 m1. Detection and analysis was performed
on the ABI 7500 Real-Time PCR System with the ABI 7500
System Sequence Detection Software Version 1.3.1. PCR was
performed for forty cycles with the following parameters:
2mins at 50◦C, 10mins at 95◦C, and for each cycle 15s at
95◦C for denaturation and 1min at 60◦C for transcription.
All samples were measured in triplicates and normalized
with beta actin. The lowest limit of detection is CT = 35.
SemiquantitativePCRwasperformedasdescribedbefore
[19] for 35 cycles. The PCR products were separated on
agarose gels, and band intensities were quantiﬁed with Gene
Tools analysis software (SynGene, Cambridge, England) and
normalized against GAPDH or beta actin and expressed as
relative quantitation (RQ). Table 1 lists the genes, primer
sequences, annealing temperature, and the size of the PCR
products.
2.4. Flow Cytometry Analysis. Bladders were harvested,
placed in RPMI-1640, and cut into smaller pieces before
digestion with collagenase (Sigma-Aldrich) for 30mins at
37◦C. The suspension was ﬁltered through a 70μmc e l l
strainer (BD, Franklin Lakes, NJ, USA) and centrifuged at
10.4g for 5mins at 4◦C. The samples were incubated in
RBC lysis buﬀer (150mM NH4Cl, 10mM KHCO3,a n d
0.1mMEDTA) for 5mins at room temperature and rinsed
twice in cold PBS. The number of cells in each sample was
enumerated with a haemocytometer. Pooled samples were
resuspended in buﬀer containing 1% (w/v) BSA and 0.01%
sodium azide in 1xPBS. Samples were assessed for T cellsClinical and Developmental Immunology 3
Table 1: Primer sequences, annealing temperature, and fragment length of PCR products.
Gene Primer sequence (5 –3 ) Temp. (◦C) Size (bp)
ACTB F ACATGGAGAAGATCTGGCAC 58 660
ACTB R CAGACAGCACTGTGTTGGCA
CCL2 F GCATCCACGTGTTGGCTCAG 60 383
CCL2 R CACACTGGTCACTCCTACAG
CCL22 F CGTCCTTCTTGCTGTGGCAA 60 233
CCL22 R CTTCTTCACCCAGACCTGCC
CCL3 F GCAACCAAGTCTTCTCAGCG 58 194
CCL3 R CTTGGACCCAGGTCTCTTTG
CCL5 F GGTACCATGAAGATCTCTGC 51.5 286
CCL5 R CTATCCTAGCTCATCTCC
CCR2 F GAGCCTGATCCTGCCTCTAC 58 371
CCR2 R GGCACTGTTTGAAGAGACGT
CD80 F GCAGGATACACCACT 55 480
CD80 R GGAAGCAAAGCAGG
CSF2 F TGGCCTGGGCTTCCTCAT 60 311
CSF2 R GGATGACATGCCTGTCAC
CXCL10 F CGTGGTCACATCAGCTGCTA 58 244
CXCL10 R TAGAACTGACGAGCCTGAGC
CXCL11 F AGGTCACAGCCATAGCCCTG 62 251
CXCL11 R CCTGCATTATGAGGCGAGCTTGC
FOXP3 F TCGTAGCCACCAGTACTCAG 57 386
FOXP3 R ATCTACGGTCCACACTGCTC
GAPDH F CACCCTGTTGCTGTAG 60 900
GAPDH R GTCGGTGTGAACGGAT
GATA3 F GATAGCATGAAGCTGGAGACG 60 500
GATA3 R AAGCTTGTAGTACAGCCCACA
IFNg F ACTGCCACGGCACAGTC 60 389
IFNg R CCGCTTCCTGAGGCTG
IL12a F CCATCGATGAGCTGATGCAG 58 340
IL12a R ATGCTGAGGTAGCTGTGCCA
IL13 F TGTCTCTCCCTCTGACCC 60 201
IL13 R TACAGAGGCCATGCAATATCC
IL15 F ATGAACTGCTTTCTCCTGGAA 60 205
IL15 R TGGACAATGCGTATAAAGCTTTGC
IL17 F CCAGGGAGAGCTTCATCTGT 58 431
IL17 R AAGATGCTGGTGGGTGTGGG
IL1b F GGCAACTGTTCCTGAACTCAACTG 62 739
IL1b R GCTTGTCTGCTGCTTGTGAGGTGC
IL2 F TGATGGACCTACAGGAGCTCCTGAG 60 191
IL2 R GAGTCAAATCCAGAACATGCCGCAG
IL6 F GATGCAACCAAACTGGATATAATC 60 225
IL6 R GAGCATTGGAAGTTGGGGTA
NOS2 F AAAGCCACGAGGCTCTGACA 58 259
NOS2 R ACCATCACGCTCGAGGTTGA
PTGS2 F ATGCTCTTCCGAGCTGTGCT 55 239
PTGS2 R GTGGGTCAGGATGTAGTGCA
TBET F CTAAAGCTCACCAACAACAAG 55 840
TBET R GTTGGGAAAATAATTATAAAA4 Clinical and Developmental Immunology
Table 1: Continued.
Gene Primer sequence (5 –3 ) Temp. (◦C) Size (bp)
TGFb1 F CTGCAAGACCATCGACAT 55 580
TGFb1 R ACAAGAGCAGTGAGCGCT
TNF F TGCACCACCATCAAGGACTC 58 360
TNF R CAGCTCAGCTCCGTTTTCAC
using ﬂuorescein isothiocyanate- (FITC-) conjugated anti-
CD3, phycoerythrin- (PE-) conjugated anti-CD4 and anti-
CD8a. Macrophages and NK cells were detected with anti-
Mac3-FITC and anti-Pan NK-PE. All antibodies were from
BD. Flow cytometry was performed on a CyAnADP (Dako
Cytomation, Sweden). The data obtained was analyzed with
the Summit software.
2.5. Statistical Analysis. The SPSS statistical package (SPSS,
Ill, USA) was used to analyze statistical signiﬁcance. The
t-test for equality of means was used to analyze the gene
expressions of two groups of animals (normal and tumor
bearing).Toanalyzevariancebetweenthegeneexpressionsin
the diﬀerent groups of animals, one-way ANOVA (Bonfer-
roni) was used. Bivariate correlation was used to analyze
correlation between two arrays. A P value of ≤0.05 was
deemed to be signiﬁcant.
3. Results
3.1.TumorGrowthandGeneExpression. Themurinebladder
cancer cell line MB49 was modiﬁed to secrete PSA so that
PSA levels could be used as a surrogate marker for the
presence of tumors [8]. MB49-PSA, like the parental MB49,
is fairly immunogenic, and some mice were spontaneously
cured (35%) after tumor implantation. MB49 cells express
the HY antigen as they were originally isolated from a male
mouse [20] as well as BLCA-4, PSCA, and STEAP [21]a n d
consequently are immunogenic, and some mice may become
cured without any therapy [6, 7]. The tumor implantation
technique used has a 100% implantation eﬃciency [17], and
this was conﬁrmed by measuring PSA secretion in the urine.
The growth of the tumors in the bladder was also monitored
by measuring urinary PSA levels. Figure 1(a), top right panel
shows tumor bearing bladders harvested at day 7, when the
tumors were small and at day 28 (bottom right panel) when
the tumors were large. In all mice, an initial increase in
urinary PSA secretion was observed at day 11 but later as
some mice were cured, PSA secretion decreased, Figure 1(b).
To conﬁrm the presence of tumors at the point of termi-
nation of the study, PSA mRNA levels were determined by
real-time PCR analysis, Figure 1(c). This is especially impor-
tant in mice with low PSA protein levels in urine as real-time
PCR analysis is a more sensitive method to conﬁrm the pres-
ence of tumors. RNA isolated from samples with conﬁrmed
tumors was used to probe a real-time gene expression
array of cytokine/chemokine genes. For each time point,
two independent samples were analyzed on the arrays. The
correlation between the arrays is shown in Figures 1(d)
and 1(e). The data from the day 7 arrays showed greater
homology than those from the day 28 arrays indicating
the greater diversity of the evolving tumor and the tumor
microenvironment. To validate the array data, 9 genes were
selected to be reconﬁrmed by real-time PCR using the same
mice samples that were used on the array. The LDA data was
comparable with the data obtained from real-time analysis,
Figure 1(f) conﬁrming the validity of the array data.
The genes up- and downregulated on both arrays are
summarized in Figure 1(g). Seventeen genes were upreg-
ulated in both day 7 and day 28 bladders as shown in
Figure 1(g). At Day 7, proteins associated with MHC class
Ia n dI Ir e c e p t o r s( β2M, CD3e, H2-EB1, HMOX1, and
PTPRC) and monocytes and dendritic cells (CD40, CD80,
and CD86) chemokine and cytokine genes (CCL2, CCL5,
CSF3, CXCL10, CXCL11, GZMB, IFNγ,I L 1 b ,N O S 2 ,P G K 1 ,
PRF1, SOCS1, and TNF) and receptors (IL2ra) attach-
ment and traﬃcking proteins (CCR2, VCAM1) and the
transcription factors that regulate their expression (STAT1,
NFKB2) were upregulated. Genes upregulated uniquely by
day 28 include CCL3, CCR7, CD8a, CSF2, FASL, IL10,
IL1a, IL6, PTGS2, and STAT4. IL10, PTGS2, and FASL
are known to suppress the immune response and SMAD7
which inhibit TGFβ, and bone morphogenetic protein
expression was downregulated which would lead to an envi-
ronment favoring tumor growth. But there were increased
CSF2, CCL3, and IL6 which would recruit immune cells
as well as increased CD8a expression. Thus, the tumor
environment is a dynamic one with inﬁltrating immune cells
trying to destroy the tumor in an environment that can be
inhibitory to their activation and/or action.
3.2. Validating Gene Expression Changes and Immune Cell
InﬁltrationinTumorBearingMice. Tovalidatethearraydata,
the expression of selected genes was assayed in other mice.
This included 17 of the diﬀerentially expressed genes from
Figure 1(g) and 12 that were determined to be similar to
controls. The expression of these genes in MB49 cells was
also examined. Table 2 summarizes the results of the analyses
which were performed using either real-time analysis or
semiquantitative PCR.
Several of the genes, whose expression was increased in
the bladder at day 7, were found to be expressed by MB49
cells, such as CSF2, PTGS2, CXCL10, TGFβ1, CCL2, and
CCL5. The increased expression of IFNγ in the bladder at
day7isprobablyduetoCXCL10beingsecretedbythetumor
cells (Table 2), but MB49 itself does not express IFNγ.
Increased expression of CD80, GZMB, and CTLA4 is
probably due to immune cell inﬁltration of the bladder atClinical and Developmental Immunology 5
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Figure 1: An orthotopic murine model of bladder cancer was established and gene expression analysis performed on day 7 and day 28.
(a) Neovascularization was apparent in the bladders 7 days after tumor implantation (upper panel), and after 28 days, the tumor-bearing
bladder appeared highly vascular and larger than normal bladders (lower panel). (b) Tumor growth was monitored by measuring urinary
PSA which was normalized with creatinine. (c) To conﬁrm the presence of tumors, PSA gene expression in the bladder was analyzed by
real-time PCR when the mice were culled at day 7 and day 28. Gene expression in the bladder was analyzed using the LDA arrays and 2
individual mice bladders. The scatter diagrams show the relationship between the RQ values of the 2 arrays of the 2 mice for the (d) day 7
and (e) day 28 bladders. The axes of the scatter diagrams are in the logarithmic scale. The middle line is the best-ﬁt line and the two lines
ﬂanking represent the 95% conﬁdence interval. r is the Pearson’s correlation, and p is the signiﬁcance level. To reconﬁrm the array data
several genes were reanalyzed by real-time PCR using the same murine samples. (f) The log (RQ) shows the same proﬁle for all the genes
evaluated. The 11 genes are (1) AGTR2; (2) CTLA4; (3) IFNγ; analyzed on RNA from mouse sample one and (4) AGTR2; (5) CSF2; (6)
CTLA4; (7) CXCR3; (8) GZMB; (9) IFNγ; (10) PTGS2 and (11) TNFα analyzed on RNA from mouse sample 2. (g) A summary of genes
with increased or decreased expression on days 7 and 28 after tumor implantation.
day 7. By day 28, GZMB and CTLA4 were still signiﬁcantly
increased and CD80 was elevated compared to control
animals. Immune cells in the bladder at day 28 were
analyzed using ﬂow cytometry, Table 3. There was increased
CD3+CD8+ in the bladder at day 28 which was consistent
with the increased CD8a expression noted on the array.
B cells were signiﬁcantly increased in the bladder at day 28,
Table 3. The presence of CTLA4 may explain the lack of
tumor reduction despite inﬁltrating immune cells. CTLA4
binds to CD80 on antigen-presenting cells and blocks the
activation of T cells. The transcription factors TBET, GATA3,
and FOXP3 regulate TH1, TH2, and Treg development.6 Clinical and Developmental Immunology
Table 2: Relative expression of genes in C57BL/6 mice bearing bladder tumors.
Day 7 Day 28
Gene Control (7) Tumor (12) Control (11) Cured (4) Tumor (15)
Realtime†
AGTR2 0.871 ± 0.123 0.231 ± 0.250∗ 1.381 ± 0.623 1.072 ± 0.251 0.171 ± 0.205∗
CSF2 0.944 ± 0.218 26.07 ± 28.00∗ 2.621 ± 5.554 1.637 ± 0.443 38.10 ± 37.28∗
CTLA4 1.088 ± 0.567 38.27 ± 36.06∗ 2.421 ± 6.216 3.026 ± 0.834 47.19 ± 30.92∗
GZMB 0.927 ± 0.312 27.07 ± 25.39∗ 0.966 ± 0.291 2.495 ± 0.456 7.349 ± 7.158∗
IFNg 1.178 ± 0.455 127.5 ± 127.9∗ 0.726 ± 0.542 2.005 ± 0.742 8.875 ± 10.89∗
IL10 5.022 ± 8.895 17.94 ± 36.01 1.377 ± 0.981 2.526 ± 0.975 3.749 ± 2.838∗
PTGS2 1.126 ± 0.781 2.424 ± 0.789∗ 1.245 ± 0.844 3.818 ± 3.132 3.040 ± 6.290
TGFb1 0.934 ± 0.302 2.450 ± 2.500 1.251 ± 0.576 3.885 ± 3.301 2.110 ± 1.439
TNF 0.956 ± 0.155 11.36 ± 12.66∗ 2.658 ± 5.417 3.333 ± 2.303 8.008 ± 14.67
PSA 2.157 ± 1.898 126.7 ± 163.7∗ 0.491 ± 0.532 0.095 ± 0.099 243.4 ± 258.1∗
RT-PCR
CCL2 1.140 ± 0.510 2.200 ± 0.840 0.799 ± 0.398 1.350 ± 0.616 1.996 ± 0.630∗
CCL22 0.063 ± 0.026 0.212 ± 0.062∗ 0.095 ± 0.019 0.139 ± 0.050 0.108 ± 0.070
CCL3 0.193 ± 0.340 0.073 ± 0.044 0.928 ± 0.397 1.699 ± 2.210 2.366 ± 1.533
CCL5 0.308 ± 0.206 0.613 ± 0.284 0.360 ± 0.050 0.670 ± 0.170 0.680 ± 0.090∗
CD80 0.094 ± 0.055 0.367 ± 0.094∗ 0.016 ± 0.008 0.134 ± 0.268 0.631 ± 0.825
CXCL10 2.383 ± 1.339 591.9 ± 257.8∗ 1.854 ± 1.257 4.831 ± 2.943 17.04 ± 30.28
CXCL11 0.523 ± 0.351 1.445 ± 0.374 0.297 ± 0.390 0.854 ± 0.656 2.240 ± 2.576∗
FOXP3 0.016 ± 0.007 0.217 ± 0.203 0.042 ± 0.018 0.068 ± 0.058 0.155 ± 0.141
GATA3 0.901 ± 0.327 0.118 ± 0.039∗ 0.858 ± 0.173 0.935 ± 0.203 0.584 ± 0.244
IL12a 0.014 ± 0.008 0.064 ± 0.031∗ ———
IL13 0.020 ± 0.010 0.600 ± 0.220∗ 0.118 ± 0.277 0.060 ± 0.063 0.033 ± 0.013
IL15 1.295 ± 0.685 0.773 ± 0.381 0.298 ± 0.149 0.218 ± 0.255 0.225 ± 0.189
IL1b 0.125 ± 0.230 1.174 ± 0.578∗ 0.006 ± 0.003 0.011 ± 0.005 0.211 ± 0.177
IL2 0.681 ± 0.714 0.994 ± 0.609 2.098 ± 1.635 1.764 ± 0.804 1.582 ± 1.329
IL6 1.550 ± 0.670 3.190 ± 0.710∗ 0.829 ± 0.099 1.482 ± 1.026 4.957 ± 2.054∗
NOS2 0.580 ± 0.100 0.950 ± 0.230∗ ———
TBET 0.057 ± 0.009 0.051 ± 0.013 0.083 ± 0.068 0.097 ± 0.068 0.075 ± 0.035
Note. The sample size for each group is indicated in brackets and “—” indicates not done. †Data is presented as the mean RQ ± SD. ∗indicates P<0.05 with
respect to control.
GATA3 was low in the bladder of tumor-bearing mice at
day 7, and FOXP3 was increased indicating the presence of
suppressor cells.
Using PSA expression as a measure of tumor size, we
segregated the mice as cured and mice bearing small tumors
(mean PSA expression 73.03 ± 69.92), medium tumors
(mean PSA expression 311.2 ± 45.85), and large tumors
(mean PSA expression 1602 ± 1914) for the day 28 samples,
Table 4.TherewereaclearandsigniﬁcantdecreaseinAGTR2
expression and increase in CTLA4 and GMCSF expression
with increasing PSA levels. Further, it appeared that the large
tumors expressed high levels of TH1 cytokines like IFNγ and
evenTNFα.Thus,theremustbeimmune-suppressivefactors
blocking tumor eradication.
As a further test of the robustness of the data obtained,
another mouse tumor model, C3H mice bearing MBT-2
tumors, was also evaluated. About 36.8% (7/19) of the genes,
namely,CSF2,TNFα,CCL22,CXCL10,IL13,IL1b,andIFNγ
were signiﬁcantly upregulated in both mice models by day 7.
Table 3: Immune cells present in the bladder at day 28.
Markers Control Tumor
CD3+CD4+ 0.593 ± 0.577 1.387 ± 1.171
CD3+CD8a+ 0.000 ± 0.000 2.460 ± 0.716∗
CD4+CD25+ 4.203 ± 4.076 1.810 ± 0.605
CD45R/B220+ 0.043 ± 0.075 2.037 ± 0.926∗
pan-NK+ 7.003 ± 1.851 5.613 ± 2.470
Mac3+ 9.670 ± 1.769 14.54 ± 6.187
∗denotes P<0.05 with respect to control.
3.3.TheImmuneEnvironmentShapestheTumor. Tomonitor
the change in gene expression with time, bladders were also
harvested at day 14 and 21 after tumor cell implantation and
examined for the expression of IFNγ, CXCL10, TGFβ, IL10,
and PTGS2. IL10 and IFNγ were chosen as these are not
produced by the tumor cell line and their presence denotes
expression by immune or other urothelial cells. Further,Clinical and Developmental Immunology 7
Table 4: Bladder gene expression at day 28 segregated by PSA expression.
Day 28
Group Control Cured Tumor (small) Tumor (medium) Tumor (large)
Gene/no 11 4 5 6 4
PSA 0.491 ± 0.532 0.095 ± 0.099 73.03 ± 69.92 311.2 ± 45.85 1602 ± 1914∗
AGTR2 1.381 ± 0.623 1.072 ± 0.251 0.342 ± 0.249∗ 0.018 ± 0.011∗ 0.187 ± 0.130∗
CSF2 2.621 ± 5.554 1.637 ± 0.443 18.16 ± 21.55 28.88 ± 12.69 76.86 ± 52.56∗
CTLA4 2.421 ± 6.216 3.026 ± 0.834 16.42 ± 15.00 68.02 ± 26.53∗ 54.42 ± 21.72∗
GZMB 0.966 ± 0.291 2.495 ± 0.456 8.394 ± 11.47∗ 5.305 ± 2.977 9.108 ± 5.886∗
IFNg 0.726 ± 0.542 2.005 ± 0.742 10.54 ± 15.36 4.594 ± 3.200 13.22 ± 12.45∗
IL10 1.377 ± 0.981 2.526 ± 0.975 5.493 ± 4.593∗ 3.301 ± 1.454 2.677 ± 2.072
PTGS2 1.245 ± 0.844 3.818 ± 3.132 1.877 ± 2.350 4.594 ± 10.00 2.163 ± 1.499
TGFb1 1.251 ± 0.576 3.885 ± 3.301 1.669 ± 1.321 1.826 ± 0.698 2.835 ± 2.072
TNF 2.658 ± 5.417 3.333 ± 2.303 3.148 ± 3.013 3.721 ± 1.815 20.51 ± 26.49∗
Data is expressed as the mean RQ ± SD. N: number of mice samples analyzed; “—”: not done. “∗” Signiﬁcant (P<0.05) with respect to control.
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Figure 2:Monitoringgeneexpressionchangesinthebladderdaysaftertumorimplantation.Thegenesanalyzedwere(a)CXCL10;(b)IFNg;
(c) TGFb; (d) PTGS2; (e) IL10; (f) PSA. Samples obtained from normal healthy bladders are labeled N, those from tumor bearing mice are
labeled T, and samples obtained from cured mice are labeled C. Each point represents one murine bladder sample. ∗ indicates a signiﬁcant
diﬀerence (P < 0.05) with respect to all the other groups.
both these cytokines were upregulated in the two tumor
models that were evaluated. IFNγ decreased with time as did
CXCL10, but not as dramatically as CXCL10. This was not a
result of tumor reduction but of the process of selection for
a less immunogenic cell type as PSA levels did not decrease
as dramatically (Figures 2(a) to 2(d)). Analysis of day 14 and
day 21 samples showed that the decrease in CXCL10 from
days 7 to 14 was followed by a concomitant increase in IL10
over the same period. Thus, while the tumor changes the
environmentinthebladder,asshownbytheincreaseinIFNγ
and IL10, it too is changed by the activity of the immune
cells recruited to the bladder which selectively destroy the
immunogenic cells and thus encourage the survival of less
immunogenic cells.
4. Discussion
A comparison of the gene expression patterns in tumor-
bearing animals revealed the variability of gene expression,
as there were only a 55% homology at day 7 and a 41.6%
homology at day 28 in gene expression between mice. This
indicates the heterogeneous nature of the tumor cells that8 Clinical and Developmental Immunology
Layers of the
bladder wall
Transitional
Submucosa
Muscle
Fat
NK cell
C D 4Tc e l l
DC
TH2 cell
TH1 cell
Macrophages
Monocytes
Bc e l l
R e gTc e l l
Proliferating
tumor cells
Apotosising
tumor cells
↑GMCSF
↑CXCL10
↑CXCL10
↑CXCL10
↑TNFα
↑IL1β
↓GATA3
↑IL12a
↑CTLA4
↑PTGS2
↓AGTR2
↓AGTR2
↑IL10
↑IL10
↑CXCL11
IL6, IL13
↑CCL2
↑Granzyme B
↑IFNγ
↑IFNγ
↑IFNγ
↑IFNγ
↑NOS2
↑IFNγ
↑CCL22
epithelium
CD8+ Tc e l l
Figure 3: A schematic diagram that summarizes the gene expression changes and immune cells identiﬁed in bladders after tumor
implantation. Proliferating tumor cells increase the expression of GMCSF and CXCL10 which in turn recruit immune cells such as natural
killer (NK) cells, dendritic cells (DC), macrophages, and T cells to the bladder. Increased expression and production of IFNγ,T N F α,
IL12a, NOS2, and GZMB by the immune cells would inhibit tumor proliferation and induce apoptosis. Transcription factor GATA3 was
downregulated, suppressing the production of TH2 T cells. CTLA4 binds to CD80 and inhibits T-cell activation. Upregulation of PTGS2 in
either tumor or immune cells or both would have an inhibitory eﬀect on immune cells. Downregulation of AGTR2 could have occurred in
the tumor cells, normal bladder epithelia, or submucosa. The dotted arrow indicates that AGTR2 may cause apoptosis in tumor cells. Genes
that are underlined were present at both day 7 and day 28. Genes in the shaded box were found only at day 28. Genes whose expression was
upregulated are indicated by arrows pointing up, and those that were downregulated are indicated by arrows pointing down.
were implanted. As tumors grew in the bladder, there were
both sculpting of the tumor cells by immune cells as well as
suppression of the immune cells inﬁltrating the tumor by the
tumors themselves.
By day 7, IFNγ, CSF2, CXCL10, GZMB, PTGS2, TNFα,
CD80, CCL22, IL12a, IL13, IL1b, IL6, NOS2, and CTLA4
were signiﬁcantly upregulated in the tumor-bearing mice
bladdersandAGTR2andGATA3weredownregulated.These
genes could lead to active immune cell recruitment (CSF2,
CXCl10, and IFNγ) and modulation of immune cell activa-
tion(IL12a,IFNγ,CSF2,CD80,GZMB,NOS2,andCTLA4),
and the generation of an inﬂammatory environment (IL6
and IL1b). Based on the genes identiﬁed granulocytes, NK
cells and T cells would be attracted by CSF2, CXCL10, and
CCL22 to the bladder. As a consequence of the presence
of NK and T cells, there would be increased expression
of GZMB and IFNγ Figure 3.T N F α could induce direct
cytotoxic eﬀects on tumor cells [6]. The inhibitory activity
of IL13, IL1b, PTGS2, NOS2, and CTLA4 [22–26] on the
immune response would enhance tumor growth. CCL22 has
been linked to the recruitment of suppressor T cells [27],
but it also recruits other immune cells which may reduce
tumor growth in the absence of Tregs. Similarly, IL13 has
been reported to be both pro- and antitumor [22, 28].
By day 28, IL10, CCL2, CCL5, and CXCL11 which were
slightly increased at day 7 were signiﬁcantly increased in
the bladder. Also CTLA4, GZMB, IFNγ,T N F α,a n dI L 6
remained signiﬁcantly increased in the bladder, Figure 3.
When gene expression was analyzed with respect to tumor
sizes, both immunosuppressive (CTLA4) and immune stim-
ulatory (IFNγ and TNFα) genes were increased with increas-
ing tumor size.
Increased CD8 T cells and B cells were found in the blad-
der at day 28. In human urothelial cancer tissue, increased
tumor inﬁltrating CD8 T cells correlates with better disease-
free survival [29]. However, we have previously found that
immune cells recruited to the bladder are usually located
at the periphery of the tumor mass [30]a n dm a yt h u sClinical and Developmental Immunology 9
be ineﬀective in the tumor environment. This could be
caused by the immunosuppressive genes identiﬁed in this
study such as CTLA4. The MB49 cells express several tumor
antigens as do human bladder tumors [31]. It is likely that
immunosuppressive molecules induced by the tumors may
prevent the activation of an adequate immune response
against the tumor antigens. In support of this view, bladder
cancer patients receiving anti-CTLA4 therapy showed an
increase in the ratio of eﬀector to regulatory T cells as well as
tumor antigen-speciﬁc CD4 T cells [24].
AGTR2 was consistently downregulated in all tumor
bearing samples. This receptor downregulates the stimula-
tory eﬀect of EGF on the growth of prostate cancer cells
[32].AGTR2actswithTIMP3toblockangiogenesis[33],but
in AGTR2 knockout mice there was impaired induction of
peripheral angiogenesis [34]. Identifying the cells expressing
AGTR2 may clarify the likely role of AGTR2 in angiogenesis.
AGTR2 expression has been associated with apoptosis in
prostatecancercells[35].ItneedstobedeterminedifAGTR2
has a similar function in human bladder cancer cells. If it
does have a similar eﬀect, then reintroduction of this gene
may eradicate tumors in the bladder.
Genes that were upregulated at day 7 represent early
changes that have occurred in the bladder, while those that
appear later may represent genes that promote survival
of the tumor. Both MB49 and MBT-2 cells express the
chemokine CXCL10 (IP10) as do human bladder tumors
[36] and this chemokine has proinﬂammatory and angio-
static eﬀects in the tumor microenvironment [37]. FOXP3-
positive T cells and increased IL10 levels are present in
human bladder cancers [38] and in the mice models. IL1b,
IL6, GMCSF, MCSF, GCSF, and TNFα are expressed in a
human bladder carcinoma cell line [39]. Local production
of CCL2 (monocyte chemoattractant protein-1 (MCP-1)),
in patients, correlated signiﬁcantly with bladder cancer
progression [40]. CCL22 (macrophage-derived chemokine
(MDC)) and NOS2 have been shown to be expressed in
clinical tissue specimens [36, 41]. Blocking CCL22 with
siRNA during the diﬀerentiation and maturation of DC
can block Treg recruitment [42], thus this is a good target
for inhibition of tumor-induced immune suppression. IL13
suppression has both pro- and antitumor eﬀects depending
on the cell type producing it [22, 43]. A role for IL13
in human bladder cancer has not been determined as yet.
PTGS2 or cyclooxygenase 2 (COX2) was found to be positive
in 60% (368/617) of bladder cancer tissue [44]. In human
urothelial cancer, TGF beta has been shown to correlate
with disease progression [45]. Thus, the murine models
are representative of the human disease and the new genes
identiﬁed as being diﬀerentially expressed in this study may
represent new targets for therapy of human bladder cancers.
Our data shows that there are both TH1 and TH2 genes
upregulated by the presence of tumor cells. Arum et al.
who evaluated a rat orthotopic model of bladder cancer also
found that host immune response pathways were actively
upregulated after tumor implantation [46]. Any cytokine
that tilts the TH1/TH2 balance in favor of a TH1 response
may induce tumor regression. It was recently reported
that tilting the TH1/TH2 balance may block the immune
suppression of CD8 T cells by mononuclear phagocytes [47,
48]. Better therapeutic responses could be induced by not
onlyinducingTH1responsesbutalsoconcurrentlysuppress-
ing TH2 responses.
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